Additionally, in VCaP tumor–bearing mice, a single i.v. treatment with KLK2 CAR T cells resulted in robust TGI as compared with both the vehicle control–treated group and the untransduced control T-cell group, with 7/10 and 10/10 complete tumor regressions after infusion of 5 × 106 and 10 × 106 KLK2 CAR T+ cells, respectively (Fig. 5B). The gene discussed is KLK2; the disease is neoplasm.